Tadeusz J. Robak

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, J. Cavenagh, H. van de Velde, 2015, American journal of hematology.